# Presentation: 750085

## Jacques Normand, Ph.D.
Director, AIDS Research Program
National Institute on Drug Abuse

*Director, AIDS Research Program*
*National Institute on Drug Abuse*

***NIDA’s New HIV/AIDS Research Program***

## Objectives

**Update on NIDA’s New AIDS Research Program**
- CAMCODA
- NIDA Council Recommendations
- New AIDS Research Program
- Structure
- Research Priorities
**Brief Update on NIDA/NIH Collaborative Projects**
- Projects and Partners
- New HPTN Network Drug Abuse Projects

## CAMCODA Structure

**Director**

**Medical Consequence Unit**

**Human Development Unit**

**Population-Based Intervention Unit**

**Deputy Director**

- _Staff:_  20 Professionals

## NIDA AIDS FY03 AIDS Funding by  Divisions

| CAMCODA | 116,035,000 |
| --- | --- |
| DESPR | 57,707,000 |
| DTR&D | 54,204,000 |
| DNBR | 29,615,000 |
| CTN | 12,052,000 |

***NIDA AIDS FY03 AIDS Funding by  Divisions***

## NIDA Advisory Council Workgroup on HIV/AIDS

**Report on ****Findings and Recommendations**
**February, 2004**

## Structural & Procedural Recommendations

- Create new position of “Director, AIDS Research Program” reporting to NIDA’s Director
- Update policy/procedures to determine which projects qualify for AIDS funding
- Improve articulation of HIV/AIDS mission and planning process within & across Divisions/Centers
- Increase interaction across NIH, and with extramural community

## NIDA’s AIDS Research

***Program Structure***

_**AIDS Research Program**_
_**Mission:**_   Plan, develop, coordinate and integrate research
- 	   priorities within NIDA and externally.
_**Staff:**_ 	   Jacques Normand
- 	   Lynda Erinoff
- 	   Helen Cesari

- _AIDS Workgroup_
- AIDS Coding Subgroup

- _External Scientific AIDS Workgroup__ _
- TBA

## NIDA’s AIDS Workgroup Membership

**Jag Khalsa**
**Ahmed Elkashef**
**Jamie Biswas**
**Division of Basic Neurosciences and Behavioral Research**
**	****Diane Lawrence**
**	****Cora Lee Wetherington**
**	****Charles Sharp**
**	****Yu Lin**
**	****Minda Lynch**

***NIDA’s AIDS Workgroup Membership***

## NIDA’s AIDS Workgroup Membership (Cont.)

**	****Elizabeth Lambert**
**Division of Clinical Neurosciences, Development and Behavioral Treatment**
**	****Lisa Onken**
**	****Melissa Racioppo**
**	****Nicolette Borek**
**	****Ro Nemeth**
**Center for Clinical Trials Network**** **
**	****Mary Ellen Michel**

***NIDA’s AIDS Workgroup Membership (Cont.)***

## NIDA’s AIDS Workgroup Membership (Cont.)

**	****Anna Staton**
**International Program**
**Steve Gust**
**Intramural Research Program**
**	****John Schmittner**
**Office of Extramural Affairs**
**Mark Green**
**Office of Planning & Research Management**
**Stacy Gardner**

***NIDA’s AIDS Workgroup Membership (Cont.)***

## External Scientific AIDS 

***Workgroup***

_**Proposed Membership (~ 8):**_
**	****Council Members**
**	****Nominee per Division/Center **
**	****Nominee from AIDS Program**
_**Proposed Task:**_
**	****Review NIDA’s AIDS Strategic Plan**
**	****Review & make recommendations on new AIDS related **
**            ****procedural change (e.g., definition of AIDS and coding **
**            ****guidelines)**
**            ****Review NIDA’s priorities/initiatives**

## FY04 AIDS Funding by

| DPMC |  52,046,000 |
| --- | --- |
| DESPR |  121,656,000 |
| DCNDBT |  46,336,000 |
| DBNBR |  29,374,000 |
| CCTN |  11,557,000 |

***FY04 AIDS Funding by***
***NIDA Divisions***

## NIDA’s FY04 Funding By OAR Research Areas of Emphasis

- Natural History and Epidemiology        **$****54,246,859**
- Etiology and Pathogenesis		         **$****29,028,598**
- Therapeutics				         **$****12,084,141**
- Vaccines				         **$****1,983,201**
- Behavioral and Social Science	         **$****186,583,465**
- Training, Infrastructure, and
- 	Capacity Building			         **$****6,860,742**
- 7.	Information Dissemination 		         **$****1,594,994****	**

## Research Priority

***Recommendations***

- Racial/ethnic disparities
- Emphasize case finding/treatment
- HAART interactions/adherence/resistance
- Newer HIV/IDU epidemics (Russia, China, India, Eastern Europe)
- Test drug Tx for HIV prevention
- Emerging drugs (e.g., Meth/Viagra, NYC case/immunological & CNS impact )
- Sexual risk behaviors (main exposure category)
- Adolescents (developmental/decision making, impulsivity)
- Role of drug abuse on transmission (drug type, partnership, context)

**Update programs with continuous review of epidemiologic and other findings**

## Current NIDA’s AIDS

***Program Tasks***

***  ******Explore new ways to attract new AIDS PIs ***
***  ******Better integrate HIV/AIDS within and across  ***
***   ******NIDA Divisions/Centers and other NIH Institutes***
*** ******Working on Generating FY07 OAR Priorities***
***    ******(retooling priorities to establish strong presence in all Div/Ctr) ***
*** ******Will be Generating NIDA FY06 AIDS Initiatives  ***
*** ******Developing Criteria for AIDS Grants***
*** ******Will be Appointing Members to Extramural***
***  ******Scientific AIDS Workgroup***
*** ******Will be Developing NIDA’s HIV/AIDS Strategic Plan***

## NIDA’s CollaborativeProjects

| Network/Cohort  |  Collaborating ICs | NIDA’s Co-Fund |
| --- | --- | --- |
| Adolescent Trial Network |  NICHD, NIMH | $1.0/20.0M |
| Pediatric HIV AIDS Cohort Study |  NICHD, NIAID, NIMH | $3.0/12.0M |
| Centers For AIDS Research | NIAID, NCI,  NHLBI, & NIMH | $4.6/33.3M |
| Women Interagency HIV Study | NIAID, NICHD, & NCI | $0.5/18.5M |
| HIV Prevention Trial Network | NIAID,NIMH, NICHD, & FIC  | $4.4/70.0M |

## HPTN & New NIAID Network

*** ******Current Projects***
***	******Epidemiology***
***	******HIV Prevention***
***	******Drug Tx as HIV Prevention***
*** ******New Network ***
***	******Proposed protocols****** ***
***	******	******Community Scale-up; ***
***	******	******Stimulant  pharmacotherapy as HIV prevention***